GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neuraxis NRXS · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.61

+5.93%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.6m

FY2020FY2025

Net income

−$7.8m

FY2020FY2025

Free cash flow

−$6.5m

FY2020FY2025

Shareholders' equity

$3.4m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue$3.6m$2.7m$2.5m$2.7m$2.7m$1.9m
Gross profit$3.0m$2.3m$2.2m$2.4m$2.3m$1.4m
Research and development$493,611$206,107$169,315$225,610$203,414$166,798
Operating income−$7.8m−$7.7m−$6.7m−$4.4m−$3.0m−$4.1m
Net income−$7.8m−$8.2m−$14.6m−$4.8m−$3.0m−$3.7m
Diluted earnings per share-0.86-1.19-4.03-0.57-0.56-0.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$6.4m$4.8m$509,498$1.5m$760,482$2.8m
Cash and short-term investments$5.0m$3.7m$78,560$253,699$320,858$1.9m
Total liabilities$3.0m$2.7m$1.9m$7.1m$1.6m$1.1m
Debt$416,611$473,405$224,260$598,821$439,275$311,492
Shareholders' equity$3.4m$2.1m−$1.4m−$5.6m−$825,660$1.6m
Shares outstanding9m7m4m8m5m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$6.4m−$6.1m−$6.7m−$2.3m−$2.2m−$4.1m
Capital spending−$31,150−$27,776−$71,781−$61,205−$1,390−$27,719
Free cash flow−$6.5m−$6.1m−$6.8m−$2.4m−$2.2m−$4.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.9m$1.6m$968,127$811,414$894,086$895,655$761,165$666,625
Gross profit$1.7m$1.4m$826,816$675,927$747,443$756,180$656,112$569,575
Operating income−$2.1m−$1.7m−$1.7m−$2.1m−$1.7m−$2.3m−$1.5m−$1.6m
Net income−$2.3m−$1.8m−$1.7m−$2.1m−$1.7m−$2.3m−$1.4m−$1.8m
Diluted earnings per share-0.19-0.15-0.19-0.23-0.19-0.25-0.21-0.25
Cash from operations−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m
Total assets$10.0m$8.7m$6.4m$5.8m$7.1m$3.0m$4.8m$1.1m
Cash and short-term investments$8.3m$7.1m$5.0m$4.4m$6.0m$2.0m$3.7m$260,884
Debt$114,668$169,524$214,045$258,492$259,763$150,207$216,906$204,075
Shareholders' equity$6.7m$5.7m$3.4m$2.3m$4.3m$258,479$2.1m−$1.8m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.0%13.1%—
Operating income21.5%13.7%—
Net income17.7%15.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin85.2%86.6%84.6%—
Operating margin-248.4%-233.0%-209.8%—
Net margin-256.5%-311.0%-262.9%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings-5.3-2.0-0.7
Price to sales11.66.03.9

Share price return

Finished calendar years

202520242023
Return17%19%-66%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.